AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: Benralizumab
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 447
- Registration Number
- NCT02808819
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
Dapagliflozin Patient Satisfaction Survey
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 653
- Registration Number
- NCT02805283
- Locations
- 🇺🇸
Reasearch Site, Eden Prairie, Minnesota, United States
Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus
Completed
- Conditions
- Type II Diabetes Mellitus
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 511
- Registration Number
- NCT02805361
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μgOther: Placebo to TIO 18 μg
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1595
- Registration Number
- NCT02796677
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease - COPD
- Interventions
- Drug: Placebo for formoterol fumarate
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 132
- Registration Number
- NCT02796651
- Locations
- 🇺🇸
Research Site, Killeen, Texas, United States
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Phase 3
Completed
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Biological: AnifrolumabDrug: Placebo
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 559
- Registration Number
- NCT02794285
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC Study
Completed
- Conditions
- Stable COPD Patients
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT02789540
- Locations
- 🇺🇾
Research Site, Montevideo, Uruguay
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1722
- Registration Number
- NCT02783573
- Locations
- 🇺🇸
Maine Neurology, Scarborough, Maine, United States
🇺🇸Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Atlanta Center of Medical Research, Atlanta, Georgia, United States
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 1
Withdrawn
- Conditions
- Core: Relapsed or Refractory Diffuse Large B-Cell LymphomaModule 1: Non-GCB Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02780830
A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: AZD9496 (Reference)Drug: AZD9496 Variant ADrug: AZD9496 Variant BDrug: AZD9496 Variant CDrug: AZD9496 Variant D
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT02780713
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States